XML 42 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net Income (Loss) per Common Share
12 Months Ended
Dec. 31, 2018
Net Income (Loss) per Common Share
L.    
NET INCOME (LOSS) PER COMMON SHARE
The following table sets forth the computation of basic and diluted net income (loss) per common share:
 
 
 
2018
 
 
2017
 
 
2016
 
 
 
(in thousands, except per share amounts)
 
Net income (loss) for basic and diluted net income per share
 
$451,779
 
 
$257,692
 
 
$(43,421)
Weighted average common shares-basic
 
 
187,672
 
 
 
198,069
 
 
 
202,578
 
Effect of dilutive potential common shares:
 
 
 
 
 
 
 
 
 
 
 
 
Incremental shares from assumed conversion of convertible notes (1)
 
 
2,749
 
 
 
1,298
 
 
 
 
Convertible note hedge warrant shares (2)
 
 
485
 
 
 
112
 
 
 
 
Restricted stock units
 
 
1,385
 
 
 
1,800
 
 
 
 
Stock options
 
 
278
 
 
 
335
 
 
 
0
 
Employee stock purchase rights
 
 
36
 
 
 
27
 
 
 
0
 
Dilutive potential common shares
 
 
4,933
 
 
 
3,572
 
 
 
 
Weighted average common shares-diluted
 
 
192,605
 
 
 
201,641
 
 
 
202,578
 
Net income (loss) per common share-basic
 
$2.41
 
 
$1.30
 
 
$(0.21)
Net income (loss) per common share-diluted
 
$2.35
 
 
$1.28
 
 
$(0.21)

 
(1)
Incremental shares from the assumed conversion of the convertible notes was calculated using the difference between the average Teradyne stock price for the period and the conversion price of $31.70, multiplied by 14.5 million shares. The result of this calculation, representing the total intrinsic value of the convertible debt, was divided by the average Teradyne stock price for the period.
(2)
Convertible notes hedge warrant shares were calculated using the difference between the average Teradyne stock price for the period and the warrant price of $39.78, multiplied by 14.5 million shares. The result of this calculation, representing the total intrinsic value of the warrant, was divided by the average Teradyne stock price for the period.
The computation of diluted net income per common share for 2018 excludes the effect of the potential exercise of stock options to purchase approximately 0.1 
million shares and restricted stock units to purchase approximately 0.5 million shares because the effect would have been anti-dilutive.
The computation of diluted net income per common share for 2017 excludes the effect of the potential exercise of stock options to purchase approximately 0.1 million shares because the effect would have been anti-dilutive.
The computation of diluted net loss per common share for 2016 excludes the effect of the potential exercise of all outstanding stock options and restricted stock units because Teradyne had a net loss and inclusion would be anti-dilutive.